The most common treatment-related adverse events of grade 3 or worse in the linsitinib group were fatigue ( three [ 3 % ] patients vs no patients in the placebo group ) , nausea ( two [ 2 % ] vs none ) , and hyperglycaemia ( two [ 2 % ] vs none ) .